Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person8
Surrozen, Inc./DE
Company
ITG, Inc./DE/
Company
8X8 INC /DE/
Company
Dave Inc./DE
Company
VALHI INC /DE/
Company
MATTEL INC /DE/
Company
ACUITY INC. (DE)
Company
SurgePays, Inc.
Company
Primary record11
Surrozen, Inc./DE filed SCHEDULE 13D/A
(the Commission) on August 6, 2026 (the Form 10-Q), plus (ii) 6,043,321 shares of Common Stock issued in the second tranche of the Issuer's private placement which closed on October 20, 2026 (the Private Placement), as d
Surrozen, Inc./DE filed SCHEDULE 13D/A
(the Commission) on August 6, 2026 (the Form 10-Q), plus (ii) 6,043,321 shares of Common Stock issued in the the second tranche of the Issuer's private placement which closed on October 20, 2026 (the Private Placement),
Surrozen, Inc./DE filed 4
SEC form 4 filed by Surrozen, Inc./DE (CIK 1824893) on 2026-10-22.
Surrozen, Inc./DE filed 4
SEC form 4 filed by Surrozen, Inc./DE (CIK 1824893) on 2026-10-22.
Surrozen, Inc./DE filed 8-K
Item 2.02 Results of Operations and Financial Condition. On October 20, 2026, Surrozen, Inc. (the “Company”) issued a press release announcing certain financial results related to the Second Closing (as defined below). A
Surrozen, Inc./DE filed SCHEDULE 13G/A
(the "Commission") on August 6, 2026 (the "Form 10-Q"). Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially ow
Surrozen, Inc./DE filed 8-K
Item 8.01 Other Events. On October 2, 2026, Surrozen, Inc. (Surrozen) announced U.S. Food and Drug Administration (FDA) clearance of our Investigational New Drug (IND) application for SZN-8141, enabling us to advance the
Surrozen, Inc./DE filed SCHEDULE 13G/A
on May 6, 2026, and (ii) 70,000 shares of common stock that Braidwell Partners Master Fund LP has the right to acquire upon exercise of the Warrants, which shares have been added to the total shares of common stock outst
Surrozen, Inc./DE filed SCHEDULE 13G/A
(the "Commission") on May 6, 2026 (the "Form 10-Q"). Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned
Surrozen, Inc./DE filed SCHEDULE 13G/A
(the "SEC") on August 6, 2026, adjusted to give effect to the 2nd Closing Shares and 2nd Closing Warrants to the extent that such securities may be acquired and exercised within 60 days hereof, as referenced herein. Row
Nasdaq Stock Market LLC filed 25-NSE
0001354457-26-000770.txt : 20260807 25-NSE 1 primary_doc.xml X0203 0001354457 Nasdaq Stock Market LLC 0001824893 Surrozen, Inc./DE 001-39635 171 Oyster Point Blvd, Suite 400 South San Francisco CA CALIFORNIA 94080 650-47